Marina Biotech Appoints Nancy R. Phelan to the Board of Directors

Marina Biotech Appoints Nancy R. Phelan to the Board of Directors

Healthcare Tech Outlook | Friday, November 30, 2018

RESEARCH TRIANGLE PARK, NC: Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis and pain, today announced that Nancy R. Phelan has been appointed to serve as a member of its Board of Directors, effective today.

Ms. Phelan is an accomplished senior executive and thought leader with over 20 years success in the healthcare and biotech industries. Since October 2018, Ms. Phelan has served as Chief Business Officer, Innate Biologics, where she is responsible for strategy, business development and operations. Since January 2018, Ms. Phelan has served as an Executive Advisor to Innate Biologics. Previously, Ms. Phelan served as Senior Vice President, Commercial Growth at Outcome Health, since July 2017. Ms. Phelan has also served since April 2018 as an Independent Board Member for FemmePharma Consumer Healthcare, since August 2018 as an Advisory Board Member for Eved, and since May 2018 as a member of the Pharma Digital Health Roundtable Steering Committee. From September 2011 until December 2016, Ms. Phelan held roles of increasing responsibility for Bristol-Myers Squibb Company (BMS), including Vice President, U.S. Customer Strategy and Operations and Head, Worldwide Commercial Operations. Prior to her time at BMS, from October 2004 until September 2011, Ms. Phelan held leadership roles in global and U.S. marketing at Wyeth, which was acquired by Pfizer Inc. in 2009. Ms. Phelan received a BA with Honors from Franklin & Marshall College and completed coursework in Villanova Universitys MBA program.

"Marina is at an exciting stage of scaling up its commercial platform and actively exploring several business development opportunities, said Robert C. Moscato, Jr., Chief Executive Officer of Marina Biotech. Nancys pharmaceutical technology and healthcare prowess will help accelerate the growth of the company and increase shareholder value.

I am delighted to join the Board of Marina, Ms. Phelan said. Marina is focused, under the leadership of Robert Moscato, on enhancing patient outcomes while leveraging its technology platform, and I am excited to work with Marina and the Board to achieve its goals.

"I am excited about Nancy joining our Board," said Dr. Uli Hacksell, Chairman of Marina's Board of Directors. "Her broad experience and expertise will nicely complement that of the other Directors."

Vuong Trieu, Ph.D. has resigned as a member of the Board of Directors to pursue other interests, effective immediately. We want to thank Dr. Trieu for his service and wish him well, Mr. Moscato said.


Weekly Brief